IP Library Granted Patent US 11,241,520
Granted Patent B2
US 11,241,520 · App. 16/749,415 · Granted Feb 8, 2022

Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,520
App. No.
16/749,415
Granted
Feb 8, 2022
Kind
B2
Abstract

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Claims (21)

1. A composition for the treatment of a medical condition, comprising:

a topical drug preparation comprising a gallate containing compound and a water-insoluble drug, where the gallate containing compound is present in an amount effective in increasing the dermal uptake of the drug, where the gallate containing compound is present in an amount by weight equal to or greater than the amount by weight of the water-insoluble drug.

2. The composition of claim 1 , where the gallate containing compound is selected from the group consisting of epi gallo catechin gallate and tannic acid.

3. The composition of claim 1 , where the drug is selected from paclitaxel, docetaxel, amphotericin, curcumin, retinoic acid, finasteride, and lidocaine.

4. The composition of claim 1 , where the drug has a molecular weight greater than 500 Daltons.

5. The composition of claim 1 , further comprising a solubilizing excipient.

6. The composition of claim 1 , where the topical drug preparation comprises a eutectic solution.

7. The composition of claim 1 , where the weight ratio of gallate containing compound:water-insoluble drug is in the range of 200:1 to 1:1, 200:1 to 5:1, 200:1 to 10:1, 200:1 to 30:1, 200:1 to 50:1, 100:1 to 1:1, 100:1 to 5:1, 100:1 to 10:1, 100:1 to 30:1, 100:1 to 50:1, 50:1 to 1:1, 50:1 to 5:1, 10:1 to 1:1, or 10:1 to 5:1.

8. The composition of claim 1 , where the topical preparation comprises a cream, paste, gel, or ointment.

9. The composition of claim 1 , where the topical preparation comprises a preblended solid or semi solid matrix of the gallate containing compound and the drug.

10. The composition of claim 1 , where the gallate containing compound and the drug are predispersed in one of a membrane, a hydrogel, an electrospun film, or a skin dressing.

11. The composition of claim 1 , where the preparation is nonaqueous.

12. A composition for the treatment of a medical condition, comprising:

a nonaqueous pharmaceutical preparation comprising a gallate containing compound and a water-insoluble drug, where the preparation is formulated to form a partially water-insoluble mass when placed in an aqueous medium, that gradually releases the drug into the aqueous medium in a controlled manner.

13. The composition of claim 12 , where the preparation is formulated to release the drug into the aqueous medium over a period of at least two days.

14. The composition of claim 12 , where the preparation is formulated to release the drug into the aqueous medium over a period of at least two weeks.

15. The composition of claim 12 , where the gallate containing compound is present in an amount effective in increasing the solubility of the water-insoluble drug in an aqueous medium.

16. The composition of claim 12 , where the gallate containing compound is present in an amount by weight equal to or greater than the amount by weight of the water-insoluble drug.

17. The composition of claim 12 , where the gallate containing compound is selected from the group consisting of epi gallo catechin gallate and tannic acid.

18. The composition of claim 12 , where the drug is selected from paclitaxel, docetaxel, amphotericin, curcumin, retinoic acid, finasteride, and lidocaine.

19. The composition of claim 12 , further comprising a solubilizing excipient selected from the group consisting of glycerol, poloxamer, propylene glycol, and polyethylene glycol.

Assignments (2)
SECURITY INTEREST Recorded Feb 28, 2024
From: COOK MEDICAL TECHNOLOGIES LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 066700/0277 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2020
From: JACKSON, JOHN K.
To: COOK MEDICAL TECHNOLOGIES LLC
Reel/Frame 053014/0299 →